A federal appeals court denied a bid by a pharmaceutical industry trade group to block a closely watched California law that bans so-called pay-to-delay deals between drug makers, a contentious issue that has factored into the larger debate over the cost of prescription medicines.

The ruling, which was issued Friday, came in response to a lawsuit by the Association for Accessible Medicines after California passed its law last fall. The state became the first in the nation to outlaw pay-to-delay deals, and California officials explained the step was necessary in order to prevent drug companies from thwarting competition and maintaining higher prices.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • As usual with Big Pharma sunshine is the best disinfectant and “pay-to-delay” is just one more egregious example of why that’s true.

    Thanks, Ed, good article and I’d love to see a challenge to the pharma trade associations to show us their math, no erasers allowed.

    Pardon the cynicism (not really) and always remember Rule #1: when two or more pharma companies do a deal rest assured the patient is the loser. There’s rare exceptions that happen about as often as Trump tells the truth.

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy